Nuvilex, Inc., Johnson & Johnson, and Medtronic, Inc., All Developing Type of Artificial Pancreas for Diabetics
(firmenpresse) - NEW YORK, NY -- (Marketwired) -- 07/02/13 -- While Medtronic, Inc. and Johnson & Johnson are developing devices that can essentially act as a type of "artificial pancreas," Nuvilex, Inc.'s (OTCQB: NVLX) unique cell encapsulation technology has shown it too can develop a type of "artificial pancreas" in preclinical diabetes studies. Their approaches couldn't be more different; however, all three companies are convinced that developing an artificial pancreas offers diabetics the best solution to independently monitor their blood sugar levels, and in turn, provide them with insulin when needed.
At the end of June, both Medtronic and Johnson & Johnson presented results from separate studies using their medical insulin pumps at the American Diabetes Association meeting in Chicago. The idea behind the "smart" pumps is to mimic a healthy pancreas by offering diabetics a type of artificial pancreas that can successfully monitor changes in blood sugar levels and then adjust the insulin being delivered to the diabetic in response to those changes.
As the two NYSE-traded companies turn to medical devices to act as their brand of artificial pancreas, the small, Silver Spring, Maryland-based biotech, Nuvilex, is turning to a much smaller and different option -- transplanted living, insulin-producing cells enclosed in capsules about the size of the head of a pin, that form a bundle and act as a miniature cell factory that produces insulin upon demand inside the diabetic's body.
According to the International Diabetes Federation, 371 million people around the world have been diagnosed with diabetes and another 187 million remain undiagnosed. As the number of diagnosed diabetics around the world grows, so too does the market for a solution. By 2020, the market for diabetes medicines and treatments is projected to reach $65 billion worldwide.
Continue reading this article at .
About Stock Market Media Group
Stock Market Media Group is a full service Investment Relations firm specializing in Research and Content Development. It offers a platform for CEOs to tell their story through the media with Research Reports, CEO Interviews and Feature Articles while building a library of Research for Investors to become better informed on small cap companies. For more information:
Contact:
Stock Market Media Group
(646) 397-4020
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 02.07.2013 - 12:30 Uhr
Sprache: Deutsch
News-ID 275039
Anzahl Zeichen: 0
contact information:
Town:
NEW YORK, NY
Kategorie:
Health & Nutrition
Diese Pressemitteilung wurde bisher 259 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Nuvilex, Inc., Johnson & Johnson, and Medtronic, Inc., All Developing Type of Artificial Pancreas for Diabetics"
steht unter der journalistisch-redaktionellen Verantwortung von
Nuvilex, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
